• Marvel Biosciences released preclinical results Nov. 10, 2026, showing MB-204 normalized autism-related behaviors in a mouse model associated with Phelan-McDermid syndrome.
• High-dose MB-204 showed broader behavioral benefits than its parent compound, istradefylline, an approved Parkinson's disease treatment.
• The findings support advancing MB-204 toward Phase 1 clinical evaluation for autism and related neurodevelopmental disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100600PRIMZONECNPR____9874090) on November 10, 2026, and is solely responsible for the information contained therein.